Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma
Gala Vega, Daniel Morillo, Christine Riedhammer, Febe Smits, Aishee Bag, Kelly Julian, Natalia Tovar Gomis, Carmen Montes Gaisan, Maria Aranzazu Bermudez, Mansi R Shah, Ghulam Rehman Mohyuddin, Binod Dhakal, Leo Rasche, Carolina Schinke, Anita D'Souza, Aniko Szabo, Niels W C J van de Donk, Rajshekha · 2026
Read Sustained disease remission after a limited duration of bispecific antibody therapy in patients with multiple myeloma by Gala Vega, Daniel Morillo, Christine Riedhammer, Febe Smits, Aishee Bag, Kelly Julian, Natalia Tovar Gomis, Carmen Montes Gaisan, Maria Aranzazu Bermudez, Mansi R Shah, Ghulam Rehman Mohyuddin, Binod Dhakal, Leo Rasche, Carolina Schinke, Anita D'Souza, Aniko Szabo, Niels W C J van de Donk, Rajshekha (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13242627.txt.
Description
Gala Vega and colleagues report that some patients with relapsed multiple myeloma stay in remission long after stopping bispecific antibody therapy. Their study appeared in HemaSphere in 2026. These antibodies are normally given without end, until the disease returns or side effects force a stop. The team followed a multi-center group who ended treatment for other reasons and tracked remission, immune recovery, and infections during extended time off therapy.
An earlier, smaller report from the group found most such patients still progression-free at eighteen months. The larger cohort extends that picture, with remissions holding well beyond the point where the drug itself should have cleared the body. The analysis tracks how antibody-making immunity rebuilds after treatment ends, a question bearing on infection risk. Infection rates off therapy are reported alongside the remission data. The findings support studying planned, limited treatment courses instead of automatic lifelong dosing.
Catalog record
| CREATOR | Gala Vega, Daniel Morillo, Christine Riedhammer, Febe Smits, Aishee Bag, Kelly Julian, Natalia Tovar Gomis, Carmen Montes Gaisan, Maria Aranzazu Bermudez, Mansi R Shah, Ghulam Rehman Mohyuddin, Binod Dhakal, Leo Rasche, Carolina Schinke, Anita D'Souza, Aniko Szabo, Niels W C J van de Donk, Rajshekha |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 19 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |